Incyte Corp (INCY)
83.65
+1.31
(+1.59%)
USD |
NASDAQ |
Nov 08, 15:51
Incyte Revenue (TTM): 4.076B for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 4.076B |
| June 30, 2024 | 3.857B |
| March 31, 2024 | 3.768B |
| December 31, 2023 | 3.696B |
| September 30, 2023 | 3.609B |
| June 30, 2023 | 3.513B |
| March 31, 2023 | 3.470B |
| December 31, 2022 | 3.395B |
| September 30, 2022 | 3.331B |
| June 30, 2022 | 3.320B |
| March 31, 2022 | 3.115B |
| December 31, 2021 | 2.986B |
| September 30, 2021 | 2.913B |
| June 30, 2021 | 2.721B |
| March 31, 2021 | 2.703B |
| December 31, 2020 | 2.667B |
| September 30, 2020 | 2.457B |
| June 30, 2020 | 2.388B |
| March 31, 2020 | 2.229B |
| December 31, 2019 | 2.159B |
| September 30, 2019 | 2.108B |
| June 30, 2019 | 2.006B |
| March 31, 2019 | 1.997B |
| December 31, 2018 | 1.882B |
| September 30, 2018 | 1.798B |
| Date | Value |
|---|---|
| June 30, 2018 | 1.729B |
| March 31, 2018 | 1.534B |
| December 31, 2017 | 1.536B |
| September 30, 2017 | 1.419B |
| June 30, 2017 | 1.306B |
| March 31, 2017 | 1.226B |
| December 31, 2016 | 1.106B |
| September 30, 2016 | 1.023B |
| June 30, 2016 | 941.24M |
| March 31, 2016 | 857.94M |
| December 31, 2015 | 753.75M |
| September 30, 2015 | 633.84M |
| June 30, 2015 | 644.38M |
| March 31, 2015 | 580.98M |
| December 31, 2014 | 511.49M |
| September 30, 2014 | 484.59M |
| June 30, 2014 | 371.57M |
| March 31, 2014 | 373.66M |
| December 31, 2013 | 354.95M |
| September 30, 2013 | 371.72M |
| June 30, 2013 | 347.09M |
| March 31, 2013 | 331.96M |
| December 31, 2012 | 297.06M |
| September 30, 2012 | 212.10M |
| June 30, 2012 | 168.39M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
2.159B
Minimum
Dec 2019
4.076B
Maximum
Sep 2024
3.119B
Average
3.218B
Median
Revenue (TTM) Benchmarks
| Syndax Pharmaceuticals Inc | -- |
| Merck & Co Inc | 63.17B |
| Pfizer Inc | 59.37B |
| Biomarin Pharmaceutical Inc | 2.753B |
| Allogene Therapeutics Inc | -- |